A-3 Price List_Lisraya - TIBs - NA.xlsx

XLSX spreadsheet 45 KB Posted

Attached to
Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program
Solicitation number
HT9402-26-Q-9404
Issued by

About this file

This is a price list template for the Department of War (DoW) Pharmacy Uniform Formulary Blanket Purchase Agreement (BPA) and Uniform Formulary Additional Discount Program (ADP) for Targeted Immunomodulatory Biologics scheduled for the November 4-5, 2026 P&T Committee meeting. The quote submission deadline is October 26, 2026. The document covers ten newly approved drugs within the Targeted Immunomodulatory Biologics class and requires manufacturers to submit pricing information across multiple formulary scenarios and points of service, including Military Treatment Facilities (MTF), Mail Order, and TRICARE Retail. Pricing submission requirements include: BPA pricing per NDC package size and per unit for both Uniform Formulary (after step therapy) and Non-Formulary scenarios; ADP pricing based on either non-FAMP (Federal Ceiling Price) calculations with additional refund percentages or Wholesale Acquisition Cost (WAC) discounts for TRICARE Retail tiers (Tier 2 and Tier 3, after step therapy). The document notes that step therapy will apply with grandfathering provisions, requiring new patients to complete adequate trials of step-preferred agents before access to non-step-preferred agents at any point of service.

Manufacturers are instructed to submit the Quote Review Checklist and fully executed signature pages along with quote information, with pricing per unit of measure remaining constant across all available package sizes within each dispensing venue. The pricing templates contain multiple appendices for both BPA and ADP programs, with the ADP appendices distinguishing between non-FAMP-based refund calculations (with current annual Federal Ceiling Price references and standard refund calculations) and WAC-based discount structures. All data on the submission sheets is subject to use and disclosure restrictions per the document's title page restrictions.

View the file

Other files

Show all 15

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

BPA

UF BPA NDC Price List for the November 2026 DoW P&T Meeting
DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
Formulary Notes
Class Note(s): Step will apply.

Step Therapy Addendum: Grandfathering will apply. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.

Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.

The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.

Blanket Purchase Agreement Appendix – Newly Approved Drug

#1DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 120144TGXX1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
20144TGXXNFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#2DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 120144TGXX1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
20144TGXXNFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#3DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 120144TGXX1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
20144TGXXNFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#4DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 120144TGXX1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
20144TGXXNFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#5DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 120144TGXX1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
20144TGXXNFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#6DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 120144TGXX1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
20144TGXXNFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#7DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 120144TGXX1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
20144TGXXNFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#8DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 120144TGXX1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
20144TGXXNFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#9DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 120144TGXX1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
20144TGXXNFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#10DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit

Scenario 120144TGXX1UFAS1MUniform Formulary
After Step1 or moreNO QUOTE
20144TGXXNFAS1MNon-Formulary
After Step1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.

ADP (non-FAMP Discount)

UF ADP Appendix for the November 2026 DoW P&T Meeting
DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
Formulary Notes
Class Note(s): Step will apply.

Step Therapy Addendum: Grandfathering will apply. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.

Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.

* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.

Additional Discount Program Appendix – Newly Approved Drug

#1DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote
Additional Discount Program Appendix – Newly Approved Drug
#5DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote
Additional Discount Program Appendix – Newly Approved Drug
#10DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.

ADP (WAC Discount)

UF ADP Appendix for the November 2026 DoW P&T Meeting
DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
Formulary Notes
Class Note(s): Step will apply.

Step Therapy Addendum: Grandfathering will apply. A prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user at any MTF, Retail, or Mail point of service.

Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.

The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).

WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.

*The quoted WAC Discount percentage will remain static during the life of the agreement.

Additional Discount Program Appendix – Newly Approved Drug

#1DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#5DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#10DoW Uniform Formulary Class:TARGETED IMMUNOMODULATORY BIOLOGICSP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND

Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package

Scenario 120144TGXX1T2AS1MTier 2
After Step1 or more
20144TGXX1T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.

File details come from the government source that posted it. Updated .